Core Insights - Huawei's HarmonyOS 5 has surpassed 10 million terminal devices as of July 30, 2025, indicating significant user adoption and ecosystem growth [1][6][11] - The operating system has been adapted for over 40 Huawei terminal products, with more than 5,000 mainstream applications available, covering 99.9% of user usage time [1][6] - The ecosystem is experiencing a positive feedback loop of user growth, developer engagement, and enriched application scenarios, marking a transition from the initial "breaking the ice" phase to a sustainable growth cycle [6][11] Product and Market Performance - HarmonyOS 5 has seen a rapid increase in terminal numbers, with over 28,000 developer submissions and more than 260 new system features since its launch [6][11] - Huawei's smartphone market share has rebounded to 18.1% in Q2 2025, reclaiming the top position in the domestic market after more than four years [9] - Major applications like WeChat and Alipay have quickly adapted to the HarmonyOS environment, enhancing user experience and functionality [9][10] Developer and Application Ecosystem - The ecosystem now includes over 1,000 financial and service applications, catering to diverse user needs in banking, securities, and insurance [11][12] - The "one development, multi-terminal deployment" capability of HarmonyOS allows developers to create applications that run seamlessly across different devices, enhancing user experience [11][12] - Companies like Dazhihui have actively engaged in developing native HarmonyOS applications, contributing to the ecosystem's growth and user engagement [12] User Engagement and Community Support - Huawei's leadership has expressed gratitude towards partners, developers, and users for their support, emphasizing community involvement in the ecosystem's success [3][4] - The company is committed to continuously improving system experiences and sharing development benefits with ecosystem partners [12]

Core Insights - The article discusses the challenges in patient recruitment for clinical trials and how Jiangsu Zhimuyun Technology Co., Ltd. (Zhimuyun) is addressing these issues through an innovative platform model [1][2] - Zhimuyun aims to create a "positive ecological cycle" in the industry, ensuring that all parties involved in patient recruitment benefit, thereby promoting sustainable development [2][5] Company Overview - Zhimuyun has been established for two years and has quickly gained attention in the industry due to its unique platform model that integrates the recruitment needs of pharmaceutical companies with patient resource holders [1][2] - The platform operates similarly to ride-hailing services, matching pharmaceutical companies' recruitment demands with various partners who have access to patient resources, such as grassroots hospitals and physician groups [2] Recruitment Model - The recruitment model focuses on three main aspects: assessment, empowerment, and service [3] - Assessment involves a scientific evaluation of the potential benefits for patients participating in trials, ensuring informed decision-making [3] - Empowerment emphasizes transparency, using simple language to explain trial processes, risks, and rights to patients [3] - Service provides dedicated medical advisors to assist patients throughout the recruitment process, ensuring safety and convenience [3] Digital Platform Benefits - Zhimuyun's digital platform enhances pharmaceutical companies' operations across three dimensions: broad coverage, high efficiency, and low risk [4] - Broad coverage is achieved by integrating over 3,000 medical institutions and more than 3 million patient data points, particularly focusing on grassroots and community-level coverage [4] - High efficiency is realized through an AI system that quickly matches patient characteristics with trial requirements, significantly improving recruitment speed [4] - Low risk is ensured by maintaining compliance and traceability of patient information, which helps reduce regulatory risks and costs for pharmaceutical companies [4] Future Industry Impact - Zhimuyun envisions that its "positive cycle" model will lead to a more standardized and efficient clinical research process, fostering a healthier and more sustainable future for the industry [5]